Brought to you by Applied Clinical Trials, The Clinical Data Disclosure and Transparency Resource Community is the go-to web destination for comprehensive data disclosure and transparency content.
Citeline Data Shows Higher Rate of Transparency Commitment
Sept. 10, 2014
TransCelerate Issues its CSR Redaction Approach for Data Sharing
Sept. 3, 2014
ECGCP Warns About Risks of Overprotecting Data
Aug. 1, 2014
ESMO's Concerns Over Data Protection and Research
July 25, 2014
Catching Up with Data Protection
July 21, 2014
EMA Delays Decision on Clinical Trial Data Until October
July 10, 2014
Pharma Improves Care by Sharing Clinical Trial Data
June 17, 2014
Privacy Analytics Launches Transparency Solution
June 18, 2014
Clinical Data Disclosure and Transparency
January 28-29, 2015 | Philadelphia, Pennsylvania
CBI’s successful inaugural event focusing on Clinical Data Disclosure and Transparency is back for its second year! This conference is the biggest of its kind and brings together high level executives to discuss and disseminate aspects of required data disclosure in a time of industry reform. Facing heightened pressure from the EMA, NIH, EFPIA, PhRMA and ICMJE to disclose clinical trial results and be transparent about all clinical trial data, this program focuses on the implications of and approaches being taken for data sharing, ensuring compliance with regulations, navigating disclosure requirements and releasing patient-level data.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.